Granulocyte colony-stimulating factor in severe chemotherapy induced afebrile neutropenia

New England Journal of Medicine

Volumn 336, Issue 25, 1997, Pages 1776-1780

  Hartmann, Lynn C ^a   Tschetter, Loren K ^b   Habermann, Thomas M ^a   Ebbert, Larry P ^c   Steven Johnson, P ^c   Mailliard, James A ^d   Levitt, Ralph ^e   Suman, Vera J ^a   Witzig, Thomas E ^a   Wieand, H S ^a   Miller, Langdon L ^f   Moertel, Charles G ^a   Grendahl, Darryl C ^a   Herrera, Dianne M ^a  

^a MAYO CLINIC   (United States)

^b Sioux Community Cancer Consortium   (United States)

^c Rapid City Regional Gruop   (United States)

^d CREIGHTON UNIVERSITY   (United States)

^e MeritCare Hospital   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; GROWTH STIMULATION; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; LENGTH OF STAY; MAJOR CLINICAL STUDY; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; FEVER; FILGRASTIM; HOSPITALIZATION; HUMANS; INFECTION; LENGTH OF STAY; LEUKOCYTE COUNT; MIDDLE AGED; NEUTROPENIA; NEUTROPHILS; PROPORTIONAL HAZARDS MODELS;

EID: 0031003362     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199706193362502     Document Type: Article

References (23)

1. Licschkc GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocytc-macrophagc colony-stimulating factor. N EngI J Med 1992; 327:28-35,99-106.
2. Metealf D. Haemopoictie growth factors. Lancet 1989;l:825-7.
3. Groopman JE, Molina J-M, Scadden DT. Hcmatopoictic growth factors: biology and clinical applications. N Engl J Mcd 1989;321:1449-59.
4. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocytc colonystimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70.
5. Ohno R, Tomonaga M, Kobayashi T, et al. Effect of granulocyte colonystimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990;323:871-7.
6. Gerhartz HH, Engelhard M, Me users P, et al. Randomized, doubleblind, placebo-controlled, phase III study of recombinant human granulocyte-macrophagc colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphoma. Blood 1993;82: 2329-39.
7. Maher DW, Licschke GJ, Grccn M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropcnia: a double-blind, placebo-controlled trial. Ann Intern Med 1994;121:492-501.
8. Riikonen P, Saarincn UM, Makipernaa A, et al. Recombinant human granulocyte-macrophagc colony-stimulating factor in the treatment of febrile neutropenia: a double-blind placebo-controlled study in children. Pediatr Infect Dis J 1994;13:197-202.
9. Mayordomo JI, Rivera F, Diaz-Puentc MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colonystimulating factors. J Natl Cancer Inst 1995;87:803-8.
10. Anaissie E, Vartivarian S, Bodey GP, et al. Randomized comparison between antibiotics alone and antibiotics plus granulocytc-macrophagc colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropcnia. Am J Med 1996;100:17-23.
11. Bicsma B, de Vries EG, Willcmse PH, et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopcnia and fever. Eur J Cancer 1990;26:932-6.
12. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1994; 12:2471-508.
13. Idem. Update of recommendations for the use of hematopoietic coiony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996;14:1957-60.
14. Bennett CL, Smith TJ, Weeks JC, et al. Use of hematopoietic colonystimulating factors: the American Society of Clinical Oncology Survey. J Clin Oncol 1996;14:2511-20.
15. Hughes WT, Armstrong D, Bodcy GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96. [Erratum, J Infect Dis 1990;161:1316.]
16. Cox DR. Regression models and life-tables. J RStat Soc [B] 1972;34: 187-220.
17. Vellenga E, Uyl-de Groot CA, de Wit R, et al. Randomized placebocontrolled trial of granulocyte-macrophagc colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol 1996; 14:619-27.
18. Ravaud A, Chevreau C, Bonichon F, Mihura J, Bui B, Tabah I. A phase III trial of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) as corrective treatment in patients with neutropenic fever following antineoplastic chemotherapy: results of an intermediate analysis. Proc Am Soc Clin Oncol 1995;14:261. abstract.
19. Mitchell PLR, Morland BJ, Dick G, et al. Clinical benefits and cost savings of interventional G-CSF therapy in patients with febrile neutropenia following chemotherapy. Blood 1995;86:Suppl l:500a. abstract.
20. Gerhartz HH, Stern AC, Wolf-Hornung B, et al. Intervention treatment of established neutropenia with human recombinant granulocytemacrophage colony-stimulating factor (rhGM-CSF) in patients undergoing cancer chemotherapy. Leuk Res 1993;17:175-85.
21. Jones SE, Schottstaedt MW, Duncan LA, et al. Randomized doubleblind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. J Clin Oncol 1996;14:2976-83.
22. Lyman GH, Lyman CG, Sanderson RA, Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993;85:488-93.
23. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.